NIVOI BELANČEVINE HMGB-1 KOD SHIZOFRENIJE: POTENCIJALNI BIOMARKER U FAZI REMISIJE

Nivoi belančevine HMGB-1 kod shizofrenije

  • Nuryil Yilmaz Cumhuriyet University Faculty of Medicine
  • Zekeriya Yelboga Cumhuriyet University Faculty of Medicine Department of Psychiatry
  • Yavuz Yilmaz Cumhuriyet University Faculty of Medicine, Department of Psychiatry
  • Ozlem Demirpence
DOI: https://doi.org/10.5937/jomb0-28108
Ključne reči: shizofrenija, HMGB1, faza remisije i akutnog pogoršanja.

Sažetak


Uvod:  Shizofrenija je hronični mentalni poremećaj koji karakterišu akutno pogoršanje i faze remisije. Imuni sistem ima ulogu u patopsihologiji shizofrenije. Belančevina HMGB1 (eng. high mobility group box-1) je belančevina koja se stvara u makrofagima i aktivira imunoćelije da proizvode citokine. Cilj ove studije je da se procene nivoi belančevine HMGB1 kod pacijenata sa shizofrenijom i prilikom akutnog pogoršanja i u fazama remisije.

Metode: Obuhvaćeni su konsekutivni pacijenti sa shizofrenijom kod akutnog pogoršanja i u fazama remisije i upoređeni su jedni sa drugima i sa zdravim ispitanicima iste starosti i pola. Pacijenti su ispitani pomoću skale za procenu pozitivnih simptoma (SAPS), skale za procenu negativnih simptoma (SANS), kratke skale za psihijatrijsku procenu (BPRS) i globalne kliničke procene (CGI).

Rezultati: Srednji nivoi belančevine HMGB1 se nisu značajno razlikovali kod pacijenata u fazi akutnog pogoršanja u odnosu na pacijente u fazi remisije (2139±564 pg/ml vs. 2326±471 pg/ml, p=0,335) a obe grupe su imale značajno povećane nivoe od kontrolne grupe (1791±444 pg/ml, p=0,05 za akutno pogoršanje u odnosu na kontrolnu grupu, p=0,002 za fazu remisije u odnosu na kontrolnu grupu). Kod pacijenata sa shizofrenijom u fazi remisije, nivoi belančevine HMGB1 bili su u pozitivnoj korelaciji sa skalom za procenu pozitivnih simptoma (r=0,447, p=0,015), a rezultati procene BPRS (r=0,397, p=0,033) i nivoi belančevine HMGB1 bili su nezavisno povezani sa procenom BPRS.

Zaključak: Pokazalo se da su nivoi seruma HMGB1 povećani kod pacijenata sa shizofrenijom bez obzira na fazu i da su nivoi belančevine HMGB1 povezani sa ozbiljnošću simptoma prema psihijatrijskoj skali kod pacijenata u fazi remisije shizofrenije.

Reference

References
1. Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:277-86.
2. Ozbey U, Tug E, Kara M, Namli M. The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. Psychiatry Clin Neurosci. 2008;62(3):307-12.
3. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci. 2010;64(3):217-30.
4. Altamura AC, Pozzoli S, Fiorentini A, Dell'osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:63-70.
5. Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, et al. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. 2014;40(2):376-87.
6. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663-71.
7. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta. 2007;375(1-2):36-42.
8. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta. 2010;1799(1-2):149-56.
9. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003;284(4):C870-9.
10. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med. 2014;20:138-46.
11. Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry. 1990;24:73-88.
12. Overall JE. The Brief Psychiatric Rating-Scale (Bprs) - Recent Developments in Ascertainment and Scaling - Introduction. Psychopharmacology Bulletin. 1988;24(1):97-9.
13. Beneke M, Rasmus W. Clinical Global Impressions (Ecdeu) - Some Critical Comments. Pharmacopsychiatry. 1992;25(4):171-6.
14. Bedrossian N, Haidar M, Fares J, Kobeissy FH, Fares Y. Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia. Front Mol Neurosci. 2016;9:16.
15. Xiu MH, Lin CG, Tian L, Tan YL, Chen J, Chen S, et al. Increased IL-3 serum levels in chronic patients with schizophrenia: Associated with psychopathology. Psychiatry Res. 2015;229(1-2):225-9.
16. Borovcanin M, Jovanovic I, Dejanovic SD, Radosavljevic G, Arsenijevic N, Lukic ML. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia. Psychoneuroendocrinology. 2015;56:143-7.
17. Zhu Q, Li X, Hie G, Yuan X, Lu L, Song X. [Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients]. Zhonghua Yi Xue Za Zhi. 2015;95(47):3818-22.
18. Lee EE, Hong SZ, Martin AS, Eyler LT, Jeste DV. Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. American Journal of Geriatric Psychiatry. 2017;25(1):50-61.
19. Stojanovic A, Martorell L, Montalvo L, Ortega L, Monseny R, Vilella E, et al. Increased serum interleukin-6 levels in early stages of psychosis: Associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology. 2014;41:23-32.
20. Borovcanin M, Jovanovic I, Radosavljevic G, Dejanovic SD, Stefanovic V, Arsenijevic N, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response. Schizophrenia Research. 2013;147(1):103-9.
21. Weber MD, Frank MG, Tracey KJ, Watkins LR, Maier SF. Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J Neurosci. 2015;35(1):316-24.
22. Yao X, Jiang Q, Ding W, Yue P, Wang J, Zhao K, et al. Interleukin 4 inhibits high mobility group box-1 protein-mediated NLRP3 inflammasome formation by activating peroxisome proliferator-activated receptor-gamma in astrocytes. Biochem Biophys Res Commun. 2019;509(2):624-31.
23. Lee EE, Hong S, Martin AS, Eyler LT, Jeste DV. Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. Am J Geriatr Psychiatry. 2017;25(1):50-61.
Objavljeno
2020/12/18
Broj časopisa
Vol. 40 Br. 3 (2021): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2020 Nuryil Yilmaz, Zekeriya Yelboga, Yavuz Yilmaz, Ozlem Demirpence

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.